Metabolic reprogramming in the tumor microenvironment shapes immune function and therapy resistance, offering insights into ...
Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Topline data readout from Phase 1a clinical trial expected in Q1 2026 SAN DIEGO, Nov. 17, 2025 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of ...
Human fertility is suboptimal in part by error-prone divisions during early cleavage stages, which frequently result in chromosomal aneuploidy. Most human pre-implantation embryos are mosaics of ...
Casdatifan data were better on every efficacy measure evaluated, across all four monotherapy cohorts (n=121) of the Phase 1/1b ARC-20 study in late-line metastatic kidney cancer, relative to published ...
New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr ...
Version of Record: This is the final version of the article. In this study by Fang et al., the authors show how STAMBPL1 promotes TNBC angiogenesis via a feed-forward GRHL3/HIF1a/VEGFA axis. They ...
Life‐threatening pulmonary arterial hypertension (PAH) still lacks a direct therapeutic approach targeted to the molecular defects associated with the disease. Here, we focus on the impaired ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback